Meadow Creek Investment Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Meadow Creek Investment Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,520	Closed	-$47K	–	1395
2019 Q2	$47K	Hold	1,520	–	–	﹤0.01%	1285
2019 Q1	$36K	Hold	1,520	–	–	﹤0.01%	1286
2018 Q4	$21K	Sell	1,520 -5,520	-78%	-$69.7K	﹤0.01%	1263
2018 Q3	$70K	Buy	7,040 +4,496	+177%	+$73.9K	﹤0.01%	1252
2018 Q2	$52K	Buy	+2,544	New	+$53.3K	﹤0.01%	1250

Other funds holding EIDX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Meadow Creek Investment Management's EIDX Position: Q3 2019 in Review

Meadow Creek Investment Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 1,520 shares — an estimated $47K sold.

Meadow Creek Investment Management first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $70K in Q3 2018. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

Meadow Creek Investment Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Meadow Creek Investment Management sold 1,520 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $47K.
Meadow Creek Investment Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Meadow Creek Investment Management's Eidos Therapeutics, Inc. Common Stock position peaked at $70K in Q3 2018.
79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.